A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Plus Metformin Combination Therapy Compared With Placebo Plus Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Aleglitazar (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AleGlucose
- Sponsors Roche
- 10 Jul 2013 Status changed from active, no longer recruiting to discontinued, according to a Roche media release.
- 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Jun 2013 Planned End Date changed from 1 Jun 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.